Evaluation of metastatic potential of prostate cancer

  • Yoshitomo Chihara | cooninh@zb4.so-net.ne.jp Department of Molecular Pathology, Nara Medical University School of Medicine, Japan.
  • Hiroki Kuniyasu Department of Molecular Pathology, Nara Medical University School of Medicine, Japan.
  • Kiyohide Fujimoto Department of Urology, Nara Medical University, Japan.
  • Yoshihiko Hirao Department of Urology, Nara Medical University, Japan.

Abstract

We aimed to establish a method for evaluating malignant potential of prostate cancer using prostatic core needle biopsy (PCNB) before prostatectomy. If we can know the final pathological stage before treatment, we can select the most suitable therapeutic tactics. We then examined the expression of E-cadherin and type IV collagenase (MMP-9/-2), which play essential role in cancer cell invasion and metastasis. The expression ratio of MMP-9/-2 to E-cadherin (MER) is revealed as the relevant marker correlated with the final pathological stage and Gleason score by prostatectomy specimens. We next confirmed the significance of MER in PCNB, which means PCNB MER enables the prediction of the final pathologic stage at the cancer diagnosis. However, the methodology measuring MER is complicated to produce an observer-to-observer deviation. We then establish a bicolor fluorescent ISH (bicolor FISH) with a computerized fluorescence detector- based system. By this method, we can reduce an observer-to-observer deviation and a slide-to-slide deviation. The bicolor FISH-based MER is a useful tool for the preoperative evaluation of the final pathologic stage, by which we can assure a decision of prostatectomy indication.

Dimensions

Altmetric

PlumX Metrics

Downloads

Download data is not yet available.
Published
2011-06-30
Info
Issue
Section
Reviews
Keywords:
Prostate cancer - E-cadherin - Matrix metalloproteinase - VEGF - Invasion - Metastasis
Statistics
  • Abstract views: 1338

  • FULL TEXT: 244
How to Cite
Chihara, Y., Kuniyasu, H., Fujimoto, K., & Hirao, Y. (2011). Evaluation of metastatic potential of prostate cancer. Oncology Reviews, 5(2), 103-107. https://doi.org/10.4081/oncol.2011.23

Most read articles by the same author(s)